VelaVigo
A biotech developing novel therapeutics for neurodegenerative diseases through targeted neuronal pathway modulation.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $60M
AI Company Overview
A biotech developing novel therapeutics for neurodegenerative diseases through targeted neuronal pathway modulation.
Neuroscience
Technology Platform
A proprietary platform focused on modulating specific neuronal survival and synaptic function pathways implicated in neurodegeneration.
Funding History
1Total raised:$60M
PIPE$60M
Opportunities
Potential to address massive unmet needs in aging populations with a first-in-class disease-modifying therapy.
Risk Factors
High biological risk of novel neuroscience targets and the historical difficulty of developing successful CNS drugs.
Competitive Landscape
Operates in the intensely competitive and high-failure-risk neurodegenerative space, competing with large pharma and well-funded biotechs like Biogen and Denali.